FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 419 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer August 21, 2021 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... July 20, 2021 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 Load more HOT NEWS Peer-to-peer match-funding initiative raises over £4 million for cancer research Presence of Tumour and Higher Levels of LAG3-positive T-cells in the... Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer... Efficacy and Safety of Adding Antiangiogenesis Therapy to First-Line Immunochemotherapy in...
